Eucure Biopharma announced that it has entered into a collaborative agreement with ISU ABXIS Co., Ltd. Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen's humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for multiple indications using its technology platform. Eucure Biopharma will receive an upfront payment, milestone payments and royalties.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,800 KRW | +1.04% | -3.95% | +12.40% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.40% | 17Cr | |
+0.75% | 9.24TCr | |
-3.03% | 3.79TCr | |
-10.46% | 3.37TCr | |
+73.70% | 2.8TCr | |
-13.39% | 1.59TCr | |
-1.08% | 1.4TCr | |
-11.15% | 1.17TCr | |
+169.04% | 1.02TCr | |
-50.19% | 1TCr |
- Stock Market
- Equities
- A086890 Stock
- News ISU Abxis Co., Ltd.
- Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence